Imperial College Scientists Dose First Patient With 5-MeO-DMT To Examine One Of The Most Potent Psychedelics’ Effects On The Brain
Private psychedelics medicine company Beckley Psytech confirmed Monday that the first patient has been dosed in a new research study investigating the neurophysiological effects of BPL-003, the company’s novel synthetic intranasal formulation of 5-MeO-DMT (also known as mebufotenin), on the human brain. Beckley Psytech has provided the funding for this study at Imperial College London via a research grant.
The news of the study comes several weeks after the company announced an update on its two-part Phase IIa study evaluating BPL-003 in patients with treatment-resistant depression.
”We are very proud to be supporting world-leading researchers at Imperial College London to learn more about how our lead compound, BPL-003, works in the human brain,” stated Dr Rob Conley, chief scientific and medical officer at Beckley Psytech. “Literature suggests an association between intensity of psychedelic experiences and positive treatment effects, so we are keen …